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Objective: Five years after reporting our initial stent-graft repair of descending
thoracic aortic aneurysms experience, we determined the 5- to 10-year results of
stent-graft treatment and identified risk factors for adverse late outcomes.
Methods: Between 1992 and 1997, 103 patients (mean age 69  12 years) under-
went repair using first-generation (custom-fabricated) stent grafts. Sixty-two pa-
tients (60%) were unsuitable candidates for conventional open surgical repair
(“inoperable”). Follow-up was 100% complete (mean 4.5 2.5 years; maximum 10
years). Outcome variables included death and treatment failure (endoleak, aortic
rupture, reintervention, and/or aortic-related or sudden death).
Results: Overall actuarial survival was 82%  4%, 49%  5%, and 27%  6% at
1, 5, and 8 years. Survival in open surgical candidates was 93%  4% and 78% 
6% and at 1 and 5 years compared with 74% 6% and 31% 6% in those deemed
inoperable (P  .001). Independent risk factors for death were older age (hazard
ratio  1.1; P  .008), previous stroke (hazard ratio  2.8; P  .003), and being
designated an inoperable candidate (hazard ratio 1.9; P .04). Actuarial freedom
from aortic reintervention and treatment failure at 8 years was 70%  6% and 39%
 8%, respectively. Earlier operative year (hazard ratio  1.2; P  .07), larger
distal landing zone diameter (hazard ratio 1.1; P .001), and transposition of the
left subclavian artery (hazard ratio 3.3; P .008) were determinants of treatment
failure.
Conclusions: Survival after aneurysm repair using crude, first-generation stent grafts
was satisfactory in good operative candidates but bleak in the inoperable cohort,
raising the question of whether asymptomatic patients should have even been
treated. Late aortic complications were detected in many patients, reemphasizing the
importance of serial imaging surveillance.
Traditional treatment of patients with descending thoracic aortic an-eurysms is open surgical graft replacement.1 Despite progressivesurgical advances, conventional surgical repair is still associatedwith substantial morbidity and mortality, especially in elderly pa-tients with other major medical conditions.2,3Initially introduced by Dotter in 1969,4 endovascular stent-graft
treatment of arterial aneurysms was subsequently studied in animal models of
abdominal aortic aneurysm and acute aortic dissection.5,6 Parodi and coworkers7
described the successful use of stent grafts for endovascular repair of abdominal
aortic aneurysms in 1991. Our group reported the feasibility of endovascular repair
of thoracic aortic aneurysms using stent grafts in 1994.8 This was followed by
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reports demonstrating that this less invasive approach was
associated with low procedural morbidity and mortality and
acceptable early results.9-16 The long-term durability and
efficacy of stent-graft repair of thoracic aortic aneurysms,
however, remains unknown.
Our prospective observational study at Stanford Univer-
sity Medical Center using crude first-generation, custom-
made stent grafts commenced in 1992; in 1998 we reported
the results of our initial 5 years of experience (1992-1997)
in 103 consecutive patients.10 The objectives of this current
report were to assess the midterm results in this same patient
cohort and to identify risk factors portending adverse late
outcomes.
Patients and Methods
Between July 1992 and November 1997, 103 consecutive patients
underwent transluminal endovascular stent-graft placement for
repair of descending thoracic aortic aneurysms under an investi-
gational protocol approved by the Institutional Review Board.
Patient evaluation and selection, as well as the procedures, in-
volved both cardiovascular surgeons and interventional radiolo-
gists. As discussed in previous publications,8,10 in general all
patients referred with descending thoracic aortic aneurysms were
considered potential candidates for stent-graft repair if they were
older and not good surgical risk; those with suitable anatomic
characteristics for endovascular repair and adequate vascular ac-
cess were offered a stent graft. Certain younger, low-risk patients
insisted on a stent graft.
Patients
Baseline clinical characteristics of the 103 patients as well as
anatomic characteristics of the descending thoracic aortic aneu-
rysms have been described previously.10 Sixty-two of the 103
patients (60%) were judged by 1 of the surgeons to be an unsuit-
able candidate for conventional open surgical repair because of
various comorbidities, including symptomatic coronary artery dis-
ease (22%), congestive heart failure (14%), chronic obstructive
pulmonary disease (31%), renal failure (22%), previous cardiovas-
cular operations (45%), or other medical problems.10
Preprocedural Imaging
All patients underwent spiral computed tomographic angiography
(CTA) scanning with 3-dimensional reconstruction and calibrated
aortography before stent-graft placement to determine the location,
length, and diameter of the aneurysm and landing zones, as well as
to evaluate the suitability of the iliac and femoral arteries for
vascular access. Stent-graft dimensions were calculated from the
CTA images; they were oversized by 10% to 15% compared with
the landing zone diameters and were at least 30 to 40 mm longer
than the target lesions to ensure adequate wall contact and a tight
circumferential seal in the landing zones.
Device Details and Stent-Graft Placement
Details of stent-graft custom fabrication and endoprosthesis inser-
tion and deployment techniques were reported previously.8,10 In
brief, first-generation stent grafts were custom-fabricated from
modified self-expandable Gianturco Z stents (Cook, Bloomington,
Ind) covered with a woven polyester graft (Boston Scientific
Corporation, Oakland, NJ). A 22F to 24F delivery system (Cook)
was used for deployment of the device. General anesthesia was
used in all patients. Stent-graft placement was achieved by a
transfemoral approach whenever feasible. An alternative vascular
site was necessary in 42% of patients.10 Using fluoroscopic and
transesophageal echocardiographic guidance and surgical expo-
sure of the access artery, the sheath and dilator system was
advanced over a guide wire and positioned across the target lesion.
Stent grafts were then deployed after optimal positioning of the
device using a pusher rod inside the sheath. When an endoleak was
detected, additional procedures, such as additional stent-graft
placement or coil embolization, were performed as necessary.
Follow-up
The follow-up protocol included contrast computed tomography
(CT) imaging before hospital discharge, 6 months after stent-graft
placement, and yearly thereafter. Because the majority of patients
were not followed at Stanford, compliance with the imaging sur-
veillance protocol was variable. At least 1 follow-up CT scan was
available for 85% of patients surviving more than 1 year. Fol-
low-up clinical status was obtained by contacting all surviving
patients or family members and their primary care physician
between July and December 2002 and was 100% complete; fol-
low-up averaged 4.5  2.5 years (maximal follow-up  10 years;
total cumulative follow-up  422 patient-years; 48 patients re-
maining at risk at 5 years). Cause of death was determined from
death certificates, medical records, and, when available, autopsy
reports.
Definitions
Primary success was defined as complete exclusion of the aneu-
rysmal sac without any additional intervention. Secondary success
was defined as complete exclusion of the aneurysm after secondary
intervention. Endoleak was defined as radiological evidence of
blood flow outside the stent graft and was classified as primary
(diagnosed within 30 days of endovascular repair) or secondary
(diagnosed more than 30 days after intervention) according to
published guidelines.17 Aortic reintervention was defined as the
need for any surgical or endovascular interventions on the treated
aortic segment during follow-up. Treatment failure was defined as
a broad, all inclusive composite end point including (1) perioper-
ative death, (2) endoleak, (3) aortic reintervention, (4) aortic-
related death, and (5) all sudden, unexplained late deaths.
Statistical Analysis
Data are expressed as mean  standard deviation or as a propor-
tion with confidence limits. The Kaplan-Meier nonparametric
method was used to generate actuarial survival estimates, which
are reported1 standard error (SE, approximately 70% confidence
limits) and compared using the log-rank test. Actual estimates of
freedom from nonfatal events were also computed, as actuarial
estimates overestimate the probability of nonfatal complications.
To identify independent risk factors for untoward events, a mul-
tivariable forward stepwise Cox proportional hazards model was
used after exploratory analysis of 34 preoperative and periopera-
tive variables (Appendix). The P values for inclusion and retention
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of variables in the models were .10 and .08, respectively, and the
 coefficients from the multivariable equation are reported. The
magnitude of the clinical impact of predictive covariates on the
event under consideration in the Cox model is reported as an
indicator of relative risk, e, or hazard ratio (HR), but this can only
be strictly interpreted for dichotomous covariates. All statistical
analyses were performed with the SPSS program (version 10.0,
SPSS Inc, Chicago, Ill).
Results
Early Outcome
Procedural success. Perioperative mortality was 9% 
3%. The stent graft was deployed successfully in all but 1
patient, resulting in 1 surgical conversion. The primary
success rate was 73%  5%. A primary endoleak was
detected in the perioperative period in 21 patients, of which
11 underwent successful secondary endovascular interven-
tions, yielding a secondary success rate of 84%  4%.
Secondary reinterventions were unsuccessful in 3 patients,
and 7 patients had primary endoleaks that were not
addressed.
Late Outcome
Survival. Actuarial survival estimates 1, 5, and 8 years
after the procedure were 82%  4%, 49%  5%, and 27%
 6%, respectively, for all patients (Figure 1, A). As shown
in Figure 1 (B), patients judged to be reasonable surgical
candidates had a significantly better life expectancy than
those who were unsuitable for open operative repair (93%
 4% vs 74%  6% at 1 year, 78%  6% vs 31%  6%
at 5 years, and 38%  12% vs 28%  6% at 8 years,
respectively; P  .001). Among the 9 patients who were
initially discharged with an endoleak (untreated or unsuc-
cessful secondary interventions), survival was 55%  14%
and 22%  14% at 1 and 2 years, respectively. Causes of
early and late deaths are listed in Table 1.
Reintervention. Actuarial freedom from aortic reinter-
vention was 83%  4%, 77%  5%, and 70%  6% at 1,
5, and 8 years (Figure 2, A), and actual freedom from aortic
reintervention was 84%  3%, 80%  4%, and 78%  4%
(Figure 2, B). More specifically, actuarial freedom from
repeat endovascular procedure was 83% 4%, 82% 4%,
and 76%  6% at 1, 5, and 8 years, while actual freedom
from repeat endovascular procedure was 84%  3%, 83%
 4%, and 82%  4%. Actuarial freedom from aortic
reoperation was 99%  1%, 94%  3%, and 71%  10%
at 1, 5, and 8 years; actual freedom from aortic reoperation
was 99%  1%, 96%  2%, and 95%  3%.
Aortic rupture. Eleven patients sustained rupture of the
treated aortic segment (6 surgical candidates and 5 consid-
ered inoperable). Rupture was fatal in 10 patients. Actuarial
freedom estimates from aortic rupture were 98%  2%,
91%  3%, and 80%  8%, at 1, 5, and 8 years, respec-
tively (Figure 3, A), whereas actual freedom from aortic
rupture was 98% 1%, 94% 3%, and 91% 3% (Figure
3, B) at these same times.
Endoleaks. Twenty-two patients developed a new (or
secondary) endoleak during follow-up (proximal type I in 9,
distal type I in 8, proximal and distal type I leaks in 2, type
II in 2, and type III in 1). Actuarial freedom from primary
or secondary endoleak was 78%  4%, 64%  5%, and
50%  9, and actual freedom from any endoleak was 79%
 4%, 70%  5%, and 67%  5% at 1, 5, and 8 years.
Actuarial freedom from a secondary endoleak was 98% 
2%, 81% 5%, and 60% 10% at 1, 5, and 8 years (actual
estimates were 98%  2%, 89%  3%, and 84%  4%).
Figure 1. A, Overall actuarial survival estimates for all 103 pa-
tients (1 SE). For perspective, this graph also portrays survival
curve for age- and gender-matched US population. B, Actuarial
survival according to whether the patient was judged not to be a
reasonable surgical candidate for open repair (1 SE).
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Treatment failure. Actuarial freedom from the overall
composite end point treatment failure was 67%  5%, 56%
 5%, and 39%  8% at 1, 5, and 8 years, respectively
(Figure 4, A), and actual freedom from treatment failure was
67% 4%, 58% 5%, and 52% 5% (Figure 4, B) at the
same times.
Multivariable Analyses
Mortality. Multivariable analysis revealed that increas-
ing age (HR  1.1, 95% CI 1.0-1.2, P  .008), previous
cerebrovascular accident (HR  2.8, 95% CI 1.4-5.6, P 
.003), and being designated not an open surgical candidate
(HR  2.0, 95% CI 1.2-3.6, P  .03) were the significant
independent determinants of all (early and late) deaths (Ta-
ble 2). Similarly, older age, larger thoracic aortic aneurysm
maximal diameter, and presence of an abdominal aortic
aneurysm were determinants of late death (Table 2).
Reintervention. As shown in Table 3, the significant
independent determinants of aortic reintervention were
transposition of the left subclavian artery (HR  5.0, 95%
CI 1.6-15.6, P  .006) and a larger proximal landing zone
(HR  1.2/mm, 95% CI 1.0-1.4, P  .03).
Treatment failure. Cox proportional hazards model
identified earlier operative year (HR  1.2, 95% CI 1.0-1.5,
P  .07), larger distal landing zone diameter (HR  1.1/
mm, 95% CI 1.0-1.2, P  .05), and transposition of the left
subclavian artery (HR  3.3, 95% CI 1.4-7.8, P  .008) to
portend a significantly higher likelihood of treatment failure
(Table 3).
Discussion
Thoracic aortic aneurysm is a life-threatening condition
with an estimated incidence of 6 to 10 cases per 100,000
person-years.18 Although less common than aortic dissec-
tion, the prevalence of thoracic aortic aneurysms appears to
be increasing19; whether this is a real phenomenon as the
population ages or predominately just a reflection of ad-
vances in noninvasive diagnostic imaging is not known. The
natural history of untreated patients with thoracic aortic
aneurysms is characterized by progressive expansion and
eventual rupture18-21; 5-year survival in patients with unop-
erated thoracic aortic aneurysms has been estimated to
range from 15% to 55%.18,19,21 Although open surgical
graft replacement is the traditional treatment for these pa-
tients, the presence of many medical comorbidities in this
specific patient population increases the surgical risks,





Acute myocardial infarction 1 8
Aortoesophageal fistula 0 2
Aortobronchial fistula 0 1
Abdominal aortic aneurysm rupture 0 1
Cancer 1 9
Cerebrovascular accident 1 9
Cirrhosis 0 1
Congestive heart failure 0 5
Diverticulitis 0 1
Hemorrhage 1 0
Ischemic colitis 0 1
Pneumonia 0 3
Pulmonary embolism 1 0
Renal failure 0 1
Respiratory failure 1 1
Sepsis 2 2
Sudden death 0 7
Suicide 0 1
Thoracic aortic aneurysm rupture 1 3
Figure 2. A, Actuarial freedom from aortic reintervention (see text
for definition) for all 103 patients (1 SE). B, Actual freedom from
aortic reintervention (1 SE).
Demers et al Surgery for Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery ● Volume 127, Number 3 667
A
CD
especially in cases of emergency operation for aortic
rupture.2,3,22-24 Nevertheless, 5-year survival rates be-
tween 60% and 80% have been achieved in recent surgical
series.2-3,22-23
Endovascular stent-graft repair of descending thoracic
aortic aneurysms started at Stanford in 1992 as a less
invasive alternative to conventional open surgical graft re-
placement.8,10 In early reports, stent-graft treatment was
usually reserved for poor candidates for open operation.8-11
After the safety of this procedure and evidence of accept-
able short-term results were demonstrated, use of stent
grafts progressively expanded to other patients and other
thoracic aortic pathologies.13-16 Despite encouraging early-
term results and increasing enthusiasm for this new tech-
nology, only 1 study has been published describing the 5- to
10-year results of endovascular stent-graft repair of abdom-
inal aortic aneurysms (AAA),25 and no such data exist for
patients with thoracic aortic aneurysms. Therefore, this cur-
rent analysis of the midterm stent-graft effectiveness to
determine whether stent grafting provides lasting protection
from aneurysm expansion or rupture was performed before
broadening the indications for endovascular stent-graft
treatment in other patients with thoracic aortic aneurysms.26
Specific Findings of This Study
In this cohort of 103 patients who underwent endovascular
stent-graft repair of thoracic aortic aneurysms using first-
generation devices (62 of which were judged not to be
reasonable operative candidates), perioperative mortality
was 9%  3%, which is comparable to contemporary sur-
Figure 3. A, Actuarial freedom from rupture of the treated aortic
segment for all 103 patients (1 SE). B, Actual freedom from
aortic rupture (1 SE).
Figure 4. A, Actuarial freedom from treatment failure (see text for
definition) in all 103 patients (1 SE). B, Actual freedom from
treatment failure (1 SE).
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gical series. Primary and secondary technical success rates
were 73% and 84%, respectively. Paraplegia and cerebro-
vascular accident occurred in 3% and 7% of patients, re-
spectively.10 The stroke problem highlights 1 of the main
drawbacks of the primitive, first-generation devices used in
this early experience, which required manipulation of large
and stiff introducers and delivery sheaths in the diseased
ascending aorta and transverse arch.
Overall, survival at 1, 5, and 8 years was 82%, 49%, and
27%, respectively, which was considerably lower than the
expected survival for a population matched for age and
gender. Late survival in good surgical candidates (78% at 5
years) was satisfactory and comparable to contemporary
results after conventional open surgical treatment.2-3,22,23 In
patients judged not to be suitable open surgical candidates,
however, life expectancy was bleak (31% survival at 5
years) due mainly to death caused by coexistent diseases.
This finding raises the important philosophical question of
whether endovascular treatment should be offered to these
patients if they are asymptomatic. In these sick individuals
the risks of endovascular stent-graft repair may exceed the
risk inherent in just watching and waiting. Furthermore,
stent grafting does nothing to enhance the quality of life of
these ill patients. Based on data from the large EUROSTAR
AAA multicenter registry, more than 20% of high-risk
patients died within 1 year of endovascular stent-graft AAA
repair.27 They concluded that patients unfit for open oper-
ation or general anesthesia probably did not benefit from
endovascular AAA repair.
Multivariable analysis identified increasing age, previous
cerebrovascular accident, and being designated not an open
surgical candidate as independent determinants of (com-
bined early and late) death, while increasing age, increasing
aneurysm diameter, and concomitant abdominal aortic an-
eurysm were determinants of late death. These factors em-
phasize the importance of careful patient selection and
anatomic factors in determining who is a good candidate for
stent grafting.
The longer duration of follow-up reported herein allowed
detection of several late complications that were not evident
in previous publications.10-15 Overall, actuarial freedom
from treatment failure (perioperative death, endoleaks, aor-
tic reintervention, aortic-related deaths, or sudden, unex-
plained late deaths) was 67%, 56%, and 39% at 1, 5, and 8
years. Actuarial freedom from primary or secondary en-
doleak was 78%, 64%, and 50% at 1, 5, and 8 years, while
actuarial freedom from aortic reintervention was 83%, 77%,
and 70%, respectively, at these same times.
The only determinants of reintervention were transposi-
tion of the left subclavian artery (LSCA) and a larger
proximal landing zone diameter, while earlier operative
year, transposition of the LSCA, and a larger distal landing
zone diameter were independent risk factors for treatment
failure. These factors reflect the impact of our learning
curve, increasing experience, and better patient selection
criteria over time on stent-graft repair durability, as well as
the importance of anatomic factors such as favorable land-
ing zone morphology (small, minimally angulated, cylindri-
cal landing zones of adequate length). The necessity for
transposition of the LSCA was probably a surrogate reflect-
ing suboptimal proximal landing zone pathological anat-
omy.
One noteworthy finding in this study was the relatively
high incidence of late rupture of the treated aortic segment,
which occurred exclusively in patients with documented
endoleaks; the estimate of freedom from late aortic rupture
was 91% at 5 years and 80% at 8 years. This is sobering, as
open surgical graft replacement usually is associated with a
durable long-term result with only a negligible late hazard
of anastomotic problems or aortic rupture. These results
clearly indicate that endovascular stent-graft repair using
TABLE 2. Independent risk factors for early and late deaths
after endovascular repair of descending thoracic aortic
aneurysms with first-generation stent grafts according to






Early and late deaths
Age (increasing) 0.04 1.1 1.0-1.2 .008
Previous CVA 1.03 2.8 1.4-5.6 .003
Not an open candidate 0.64 2.0 1.1-3.5 .04
Late deaths
Age (increasing) 0.06 1.1 1.0-1.2 .001
Aneurysm diameter (larger) 0.03 1.1 1.0-1.2 .001
Abdominal aortic aneurysm 0.64 1.9 1.1-3.3 .02
CVA, Cerebrovascular accident.
TABLE 3. Independent risk factors for reintervention and
treatment failure after endovascular repair of descending
thoracic aortic aneurysms with first-generation stent grafts









0.13 1.2 1.0-1.4 .03
Transposition LSCA 1.61 5.0 1.6-15.6 .006
Treatment failure
Operative year (earlier) 0.21 1.2 1.0-1.5 .07
Distal landing zone
(larger)
0.09 1.1 1.0-1.2 .001
Transposition LSCA 1.18 3.3 1.4-7.8 .008
LSCA, Left subclavian artery.
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primitive, first-generation devices was palliative for the
most part.
Most of the endoleaks detected during follow-up were
related to the proximal or distal landing zones, or type I
endoleaks.17 Endoleaks, especially type I, are associated
with persistent or recurrent aneurysmal sac pressurization,
progressive expansion, and eventual rupture.25,28,29 This
serious complication of endovascular stent-graft repair
should be actively looked for during follow-up and treated
aggressively when found. Multiple factors may have con-
tributed to these late endoleaks; inadequate fixation allow-
ing stent-graft migration has been proposed as 1 factor
contributing to the development of a secondary en-
doleak.28,29 In this study, significant device migration was
not observed on imaging studies during follow-up, even in
patients developing secondary endoleaks. Poor landing zone
morphology (larger diameter, short length, abrupt angula-
tion, presence of thrombus), vector forces acting on the
endoprosthesis,29 or cantilevering the proximal stent graft
end off the lesser curve of the distal arch are other factors
that may play a role in endoleak formation. Finally, disease
progression proximally or distally, especially in patients
with diffuse degenerative aneurysms, may result in slow
enlargement of the landing zones, loss of fixation, and sac
pressurization.
Midterm Results of Endovascular Stent-Graft Repair
in the Literature
The initial results of endovascular stent-graft treatment of
thoracic aortic aneurysms have been reported, but the aver-
age follow-up interval was only 9 to 22 months.10,13-15,29
Stent grafting was fairly safe, but durability has not been
determined. Because certain complications, such as late
endoleaks, may not occur until 3 to 5 years afterward as the
aortic landing zones slowly but inexorably enlarge,25,30
previous reports may have underestimated complication
rates. Orend and associates15 analyzed a 6-year experience
with thoracic aortic stent-graft repair in 74 patients; 1 of 5
late deaths was related to stent graft, and 5 patients (7%)
required reinterventions for late aortic complications at an
average of 22 months postprocedure. Other investigators,
however, have reported a higher incidence of stent-graft
complications. Among 23 patients treated with custom-
made stent grafts and followed with a strict imaging proto-
col (median of 18 months), Resch and collaborators29 ob-
served 5 late type I endoleaks (22%), and migration of at
least 1 end of a stent graft was documented in 10 patients,
or 43%. Recently, late results of endovascular AAA repair
using first-generation stent grafts (median follow-up was 6
years) were reported: Alric and colleagues25 observed that
the actuarial estimate of freedom from AAA-related death
was only 73% at 7 years. Actuarial freedom estimates from
endoleak and surgical conversion were 49% and 50%, re-
spectively, at 7 years. Despite the small number of patients
(n  23), these authors concluded that endovascular repair
of AAA using first-generation stent grafts was associated
with suboptimal durability and failed to protect patients
from AAA-related death.25 Our observations reported
herein for thoracic aortic stent grafting can be interpreted
similarly; hopefully, more refined patient selection criteria
and improved stent-graft devices in the future will be asso-
ciated with more overall patient benefit.
Clinical Implications
First, until longer follow-up in more patients becomes avail-
able to learn definitively just how durable stent grafting is
using new commercial devices, we believe it is not prudent
to offer endovascular stent-graft repair to younger patients
who do not have major contraindications to open surgical
repair. Second, careful selection of patients for endovascu-
lar stent grafting is key, with particular emphasis placed on
identification of favorable anatomic targets, symptom sta-
tus, and projected life expectancy. Third, patients with con-
nective tissue disorders, such as the Marfan syndrome, were
not included in this study and should not be treated with
endovascular stent grafts due to the thin, weak aorta that
theoretically predisposes them to a high likelihood of de-
veloping a false aneurysm or endoleak at the proximal or
distal landing zones
Last, we can broach, but cannot definitively answer, the
philosophical question each individual physician must ad-
dress and the ethical question society must face concerning
whether stent grafting should be withheld in elderly patients
with asymptomatic aneurysms who are not open operative
candidates given the very poor survival rates reported
herein. The soberingly dismal life expectancy in patients not
judged suitable for open surgical repair cannot be blamed on
the first-generation devices used; this is a direct reflection of
patient selection criteria. What we do know is that stent
grafting in asymptomatic patients does not improve quality
of life; indeed, a cynic would term this “futile therapy” and
submit that preventing aneurysm rupture by stent grafting
only prolongs patient suffering due to their multiple other
debilitating medical diseases. Just because we can treat does
not necessarily mean we should treat. Society, and specifi-
cally health care policy planners and payors, must grapple
with these tough philosophical and ethical questions when
these devices are considered for clinical release.
Limitations
Several factors restrict the inferences that can be drawn
from these observations. First, the design of this prospective
observational study and the lack of a randomized or con-
current control group precluded direct comparison with
results achieved after conventional open surgical graft re-
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placement. Also, it is important to note that we did not have
another control group of patients matched to the “inopera-
ble” cohort who did not undergo any treatment of their
aneurysm; hence, we cannot state that these ill patients
actually lived any longer after stent grafting. It is unlikely
that stent grafting prolonged their lives, however, given
their high attrition rate over the first 3 to 5 years and the fact
that so few deaths were due to aortic complications.
Second, this series represents our earliest 5-year experi-
ence with endovascular stent grafts using primitive devices
in a rapidly evolving field. For example, in the initial years
benign-appearing endoleaks seen on an initial study were
left untreated. This mistake was soon rectified, with all
possible interventional options exercised to eliminate these
leaks before the patient left the hospital. Also, patient se-
lection criteria changed over time. We now believe that
endovascular stent grafting should be restricted mostly to
high surgical risk, elderly patients who ideally have focal
anatomic lesions associated with small, minimally angu-
lated, cylindrical proximal and distal landing zones of suf-
ficient length. Adequate vascular access, in terms of arterial
size and lack of excessive tortuosity and occlusive disease,
also needs to be considered. Due to rapidly evolving tech-
nology, the results reported herein using very crude and
cumbersome first-generation devices does not represent
what might potentially be achieved today using commercial
third-generation devices designed specifically for the tho-
racic aorta. Our results reflect our earliest clinical experi-
ence using very primitive stent grafts and therefore should
be considered a “worst case” scenario, as well as an analysis
of a “moving target.” Improved delivery systems (smaller,
not sheath-pusher rod deployed, coaxial over the wire,
sheath limited to the abdominal aorta) and device design
(flexibility to accommodate angulated distal arch anatomy,
improved fixation mechanisms, strengthened integrity, and
flexible optional features with specific characteristics ac-
cording to various indications) should be associated with
better outcomes in the future.
Third, the absence of autopsy confirmation in all patients
who died makes it difficult to substantiate the fact that
stent-graft repair prevented aneurysm rupture; to avoid un-
derestimating such possible fatal complications, we in-
cluded all late, unexplained sudden deaths in the treatment
failure composite end point. Even though this approach will
probably overestimate the incidence of complications, we
urge that this very conservative reporting definition be ap-
plied to all trials of stent grafting as it will eliminate inter-
institutional bias and reporting variability. Finally, this
study is limited by incomplete systematic, serial imaging
follow-up and unknown medical compliance after hospital
discharge; more specifically, late imaging studies were not
performed in 15% of patients for a variety of reasons.
Conclusion
In this cohort of 103 patients, 5-year survival after repair of
descending thoracic aortic aneurysms using first-generation
stent grafts was satisfactory in operative candidates but
inferior to a matched US population. Furthermore, the prog-
nosis of those deemed inoperable was very bleak; these
patients died primarily from other medical diseases and not
aortic rupture. These results raise the philosophical question
if any treatment at all should have been be offered to sick,
elderly individuals if they had asymptomatic aneurysms.
Late complications in the treated thoracic aortic segment
were detected in a substantial proportion of patients, em-
phasizing the importance of indefinite, long-term serial im-
aging surveillance. Better clinical results can be expected in
the future given the rapid technological advances occurring
in this field.
We thank our colleagues in Cardiovascular Surgery and Inter-
ventional Radiology for allowing us to include their patients.
References
1. DeBakey ME, McCollum CH, Graham JM. Surgical treatment of
aneurysms of the descending thoracic aorta: long-term results in 500
patients. J Cardiovasc Surg (Torino). 1978;19:571-6.
2. Moreno-Cabral CE, Miller DC, Mitchell RS, Stinson EB, Oyer PE,
Jamieson SW, et al. Degenerative and atherosclerotic aneurysms of the
thoracic aorta. J Thorac Cardiovasc Surg. 1984;88:1020-32.
3. Kouchoukos NT, Dougenis D. Surgery of the thoracic aorta. N Engl
J Med. 1997;336:1876-88.
4. Dotter CT. Transluminally-placed coilspring endarterial tube grafts:
long-term patency in canine popliteal artery. Invest Radiol. 1969;4:
328-32.
5. Balko A, Piasecki GJ, Shah DM, Carney WI, Hopkins RW, Jackson
BT. Transfemoral placement of intraluminal polyurethane prosthesis
for abdominal aortic aneurysm. J Surg Res. 1986;40:305-9.
6. Moon MR, Dake MD, Pelc LR, Liddell R, Castro LJ, Mitchell RS, et
al. Intravascular stenting of acute experimental type B dissections.
J Surg Res. 1993;54:381-8.
7. Parodi JC, Palmaz JC, Barone HD. Transfemoral intraluminal graft
implantation for abdominal aortic aneurysms. Ann Vasc Surg. 1991;
5:491-9.
8. Dake MD, Miller DC, Semba CP, Mitchell RS, Walker PJ, Liddell RP.
Transluminal placement of endovascular stent-grafts for the treatment
of descending thoracic aortic aneurysms. N Eng J Med. 1994;331:
1729-34.
9. Grabenwoger M, Hutschala D, Erhlich MP, Cartes-Zumelzu F, Thurn-
her S, Lammer J, et al. Endovascular stent graft repair for aneurysms
of the descending thoracic aorta. Ann Thorac Surg. 1998;66:19-25.
10. Dake MD, Miller DC, Mitchell RS, Semba CP, Moore KA, Sakai T.
The first generation of endovascular stent grafts for patients with
aneurysms of the descending thoracic aorta. J Thorac Cardiovasc
Surg. 1998;116:689-704.
11. Greenburg R, Resch T, Nyman U, Lindh M, Brunkwall J, Brunkwall
P, et al. Endovascular repair of descending thoracic aortic aneurysms:
an early experience with intermediate-term follow-up. J Vasc Surg.
2000;31:147-56.
12. Grabenwoger M, Hutschala D, Erhlich MP, Cartes-Zumeszu F, Thurn-
her S, Lammer J, et al. Thoracic aortic aneurysms: treatment with
endovascular self-expandable stent grafts. Ann Thorac Surg. 2000;69:
441-5.
13. White RA, Donayre CE, Walot I, Lippmann M, Woody J, Lee J, et al.
Endovascular exclusion of descending thoracic aortic aneurysms and
chronic dissections: initial clinical results with the AneurRx device. J
Vasc Surg. 2001;33:927-34.
Demers et al Surgery for Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery ● Volume 127, Number 3 671
A
CD
14. Cambria RP, Brewster DC, Lauterbach SR, Kaufman JL, Geller S, Fan
CM, et al. Evolving experience with thoracic aortic stent graft repair.
J Vasc Surg. 2002;35:1129-36.
15. Orend KH, Scharrer-Palmer R, Kapfer X, Kotsis T, Gorich J, Sunder-
Plassmann L. Endovascular treatment in diseases of the descending
thoracic aorta: 6-year results of a single center. J Vasc Surg. 2003;37:
91-9.
16. Dake MD. Endovascular stent-graft management of thoracic aortic
diseases. Eur J Radiol. 2001;39:42-9.
17. Chaikof EL, Blankensteijn JD, Harris PL, White GH, Zarins CK,
Bernhard VM, et al. Reporting standards for endovascular aortic
aneurysm repair. J Vasc Surg. 2002;35:1048-60.
18. Bickerstaff LK, Pairolero PC, Hollier LH, et al. Thoracic aortic aneu-
rysms: a population-based study. Surgery. 1982;92:1103-8.
19. Clouse WD, Hallett JW, Schaff HV, Gayari MM, Ilstrup DM, Melton
LJ. Improved prognosis of thoracic aortic aneurysms. A population-
based study. JAMA. 1998;280:1926-9.
20. Juvonen T, Ergin MA, Galla JD, Lansman SL, Nguyen KH, McCul-
lough JN, et al. Prospective study of the natural history of thoracic
aortic aneurysms. Ann Thorac Surg. 1997;63:1533-45.
21. Davies RR, Goldstein LJ, Coady MA, Tittle SL, Rizzo JA, Kopf GS,
et al. Yearly rupture or dissection rates for thoracic aortic aneurysms:
simple prediction based on size. Ann Thorac Surg. 2002;73:17-28.
22. Svensson LG, Crawford ES, Hess KR, Coselli JS, Safi HJ. Variables
predictive of outcome in 832 patients undergoing repairs of the de-
scending thoracic aorta. Chest. 1993;104:1248-53.
23. Kouchoukos NT, Masetti P, Rokkas CK, Murphy SF, Blackstone EH.
Safety and efficacy of hypothermic cardiopulmonary bypass and cir-
culatory arrest for operations on the descending thoracic and thoraco-
abdominal aorta. Ann Thorac Surg. 2001;72:699-708.
24. Estrera AL, Rubenstein FS, Miller CC, Huynh TT, Letsou GV, Safi
HJ. Descending thoracic aortic aneurysm: surgical approach and treat-
ment using the adjuncts cerebrovascular fluid drainage and distal aortic
perfusion. Ann Thorac Surg. 2001;72:482-6.
25. Alric P, Hinchliffe RJ, Wenham PW, Whitaker SC, Chuter TAM,
Hopkinson BR. Lessons learned from the long-term follow-up of a
first-generation aortic stent-graft. J Vasc Surg. 2003;37:367-73.
26. Chuter TAM. Endovascular aneurysm repair with the AneuRx stent-
graft is safe, but is it effective? J Am Coll Cardiol. 2001;38:1047-8.
27. Laheij RJ, van Marrewijk CJ. Endovascular stenting of abdominal
aortic aneurysm in patients unfit for elective open surgery. Lancet.
2000;356:832.
28. Harris PL, Vallabhaneni SR, Desgranges P, Becquemin JP, van Mar-
rewijk C, Laheij RJ. Incidence and risk factors of late rupture, con-
version, and death after endovascular repair of infrarenal aortic aneu-
rysms: the EUROSTAR experience. European collaborators on stent-
graft techniques for aortic aneurysm repair. J Vasc Surg. 2000;32:739-
49.
29. Resch T, Koul B, Dias NV, Lindblad B, Ivancev K. Changes in
aneurysm morphology and stent-graft configuration after endovascular
repair of aneurysms of the descending thoracic aorta. J Thorac Car-
diovasc Surg. 2001;122:47-52.
30. Holaenbein TJ, Kretschmer G, Thurnher S, Schoder M, Aslim E,
Lammer J, et al. Midterm durability of abdominal aortic aneurysm
endograft repair: a word of caution. J Vasc Surg. 2001;33:S46-54.
Discussion
Dr H. Storm Floten (Portland, Ore). I would like to thank Dr
Demers and compliment his Stanford colleagues on a very fine
report. You can always count on a class act paper out of that very
fine institution.
Now I have never put one of these things in and I have had
absolutely no experience with this. Basically I like to operate on
thoracic aneurysms, so I hope that I will try to be unbiased in my
comments. However, there are a few points that should not be
taken lightly, including the procedure mortality of 9%, the 11
patients who died of late rupture, and obviously the inoperable
patients with a 5-year survival rate of 30%. The authors have very
candidly and fairly addressed these issues. Now surgeons such as
myself like to compare these data with our surgical results and
that’s a little bit difficult here. The inoperable patients may have
been operable if the stent was not available. We all push the
envelope on operability. This changes the cohort of patients being
examined in a study like this versus our surgical results. For
example, the surgical result for descending thoracic aneurysm
repair is about 80% 5-year survival and in the good patients in this
series it is about 80% survival, so it is misleading when you add in
the inoperable patients. The patient with a cancer in the lung who
dies of lung cancer 6 months later certainly does put a negative
twist on this.
In my opinion, when I operate on thoracic aneurysms, it is rare
that I see a nice saccular aneurysm with a perfectly clean aorta on
one end and a perfectly clean aorta on the other end. The perfect
example was the picture that we saw here today. On the dye study
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it looked like an absolutely normal aorta upstream and an abso-
lutely normal downstream but I forget what it was, 2 or 3 years
later, we have a problem downstream with aorta enlarging, and we
know that the pathology of the aorta is always much greater than
the CT scan, magnetic resonance imaging, or the dye study shows.
Most of the aneurysms I operate on have a calcified arch that I am
dealing with or down at the diaphragm an aneurysm that is running
through the diaphragm; there is clot, there is a double-barrel lumen
fusiform aneurysm related to dissection. So I don’t believe that this
technology will ever do away with surgical repair of descending
thoracic aneurysms, but with increased improvement in selection
of patients and with increased improvement in technology of the
stents, I think there is a bright future for a small window of patients
in whom we will be able to do this.
I really have 1 question. We all have met the 75-year-old
grandma in the middle of the night who is hypertensive with an
acute type III dissection and we usually treat these medically and
3 days later we are called because now she has a big pleural
effusion and she is leaking. We all know that our surgical results
are dismal in this setting. Have you had any experience, Dr
Demers, or plans for any experience in dealing with this in a
prophylactic situation? It seems to me if there is a great asset to
this technology it would be in this patient in which we could
prophylactically put a stent in the location of the tear, which is
somewhere around the takeoff of the left subclavian, and protect
these people from ending up on the operating table 2 or 3 days later.
Dr Demers. Thank you, Dr Floten, for your nice comments.
Very few patients with acute or chronic type B dissection were
included in this series, so I cannot directly answer your question
with our data. We certainly don’t have experience at Stanford with
stent-graft treatment of uncomplicated acute type B dissections.
We try to treat all uncomplicated acute type B dissections medi-
cally and will consider surgical or endovascular treatment for
complicated cases. However, I am aware of a multicenter Euro-
pean trial comparing endovascular stent-graft treatment versus
medical therapy conducted right now in Europe by Dr Nienaber
from Germany. They also have another trial comparing surgical
therapy versus stent-graft repair in patients with complicated dis-
sections, so hopefully these trials will answer some of these
questions.
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